DKK151.05
0.07% today
Copenhagen, Apr 03, 04:59 pm CET
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Bavarian Nordic Stock price

DKK151.05
-16.10 9.63% 1M
-74.95 33.16% 6M
-38.30 20.23% YTD
-12.35 7.56% 1Y
-33.75 18.26% 3Y
+29.75 24.53% 5Y
-205.45 57.63% 10Y
Copenhagen, Closing price Thu, Apr 03 2025
+0.10 0.07%
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Key metrics

Market capitalization DKK11.86b
Enterprise Value DKK9.81b
P/E (TTM) P/E ratio 11.99
EV/FCF (TTM) EV/FCF 5.25
EV/Sales (TTM) EV/Sales 1.71
P/S ratio (TTM) P/S ratio 2.07
P/B ratio (TTM) P/B ratio 1.04
Revenue growth (TTM) Revenue growth -18.88%
Revenue (TTM) Revenue DKK5.72b
EBIT (operating result TTM) EBIT DKK948.35m
Free Cash Flow (TTM) Free Cash Flow DKK1.87b
Cash position DKK2.18b
EPS (TTM) EPS DKK12.59
P/E forward 9.43
P/S forward 1.87
EV/Sales forward 1.55
Show more

Is Bavarian Nordic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Bavarian Nordic Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Bavarian Nordic forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Bavarian Nordic forecast:

Buy
33%
Hold
67%

Financial data from Bavarian Nordic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5,725 5,725
19% 19%
100%
- Direct Costs 2,897 2,897
18% 18%
51%
2,827 2,827
39% 39%
49%
- Selling and Administrative Expenses 353 353
11% 11%
6%
- Research and Development Expense 863 863
61% 61%
15%
1,612 1,612
21% 21%
28%
- Depreciation and Amortization 663 663
20% 20%
12%
EBIT (Operating Income) EBIT 948 948
37% 37%
17%
Net Profit 988 988
33% 33%
17%

In millions DKK.

Don't miss a Thing! We will send you all news about Bavarian Nordic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Head office Denmark
CEO Paul Chaplin
Employees 1,611
Founded 1992
Website www.bavarian-nordic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today